Form 8-K - Current report:
SEC Accession No. 0001493152-25-028850
Filing Date
2025-12-22
Accepted
2025-12-22 17:29:32
Documents
25
Period of Report
2025-12-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 56970
2 EX-4.1 ex4-1.htm EX-4.1 135194
3 EX-4.2 ex4-2.htm EX-4.2 136806
4 EX-5.1 ex5-1.htm EX-5.1 21629
5 EX-10.1 ex10-1.htm EX-10.1 274627
6 EX-10.2 ex10-2.htm EX-10.2 89999
7 EX-10.3 ex10-3.htm EX-10.3 8639
8 EX-99.1 ex99-1.htm EX-99.1 17865
9 GRAPHIC ex5-1_001.jpg GRAPHIC 6123
10 GRAPHIC ex10-2_001.jpg GRAPHIC 27161
11 GRAPHIC ex99-1_001.jpg GRAPHIC 9114
12 GRAPHIC ex99-1_002.jpg GRAPHIC 5217
  Complete submission text file 0001493152-25-028850.txt   1161463

Data Files

Seq Description Document Type Size
13 XBRL SCHEMA FILE lixt-20251216.xsd EX-101.SCH 3784
14 XBRL DEFINITION FILE lixt-20251216_def.xml EX-101.DEF 26650
15 XBRL LABEL FILE lixt-20251216_lab.xml EX-101.LAB 36768
16 XBRL PRESENTATION FILE lixt-20251216_pre.xml EX-101.PRE 25274
28 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5311
Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251593584
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)